Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables (2016 - 2025)

Lineage Cell Therapeutics' Receivables history spans 15 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Receivables rose 144.83% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 144.83%, while the annual FY2025 figure was $1.6 million, 144.83% up from the prior year.
  • Receivables reached $1.6 million in Q4 2025 per LCTX's latest filing, up from $676000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $51.2 million in Q4 2021 to a low of $77000.0 in Q1 2024.
  • Average Receivables over 5 years is $3.1 million, with a median of $419000.0 recorded in 2023.
  • The largest YoY upside for Receivables was 1279275.0% in 2021 against a maximum downside of 99.55% in 2021.
  • A 5-year view of Receivables shows it stood at $51.2 million in 2021, then plummeted by 98.28% to $878000.0 in 2022, then dropped by 20.27% to $700000.0 in 2023, then decreased by 8.86% to $638000.0 in 2024, then soared by 144.83% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Receivables are $1.6 million (Q4 2025), $676000.0 (Q3 2025), and $256000.0 (Q2 2025).